Resources

Asia-Pacific deal activity drops 18.6% due to coronavirus

A total of 215 deals were announced in the Asia-Pacific (APAC) region during the week ended 29 March 2020, according to GlobalData’s deals database. The number marked a decrease of 18.6% when compared with 264 deals announced during the previous week. Deal...

read more

Global deal activity decreases 19.7%

A total of 837 deals were announced globally during the week ended 29 March 2020, according to GlobalData’s deals database. The number marked a decrease of 19.7% when compared with the 1,042 deals announced during the previous week. The subdued activity, which...

read more

QIAGEN receives FDA’s EUA for coronavirus detection kit

QIAGEN has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to diagnose patients infected with coronavirus (Covid-19). The newly developed test kit is the first and only...

read more

South Africa begins mass coronavirus screening

South Africa’s president Cyril Ramaphosa announced on Monday that the country will embark on a mass COVID-19 screening programme. He announced that 10,000 workers would be visiting citizens’ homes in order to carry out screenings for coronavirus symptoms....

read more

80% of scams, hacks and cyberattacks now coronavirus themed

According to cybersecurity firm Proofpoint, 80% of scams, hacks and cyberattacks are now coronavirus-themed. Since the security firm began monitoring for coronavirus scams on 29 January, it has observed over 500,000 messages, 300,000 malicious URLs and 200,000...

read more

GigaGen jumps into COVID-19 arena with polyclonal antibodies

Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. GigaGen thinks its approach...

read more

Strategic Planning In Biotech During A Pandemic Crisis

In the throes of a full COVID-19 pandemic, most business leaders’ top priority is rightfully the health and safety of their employees, families, and communities. Even though business disruptions are significant and overwhelming, the primary efforts focused on...

read more

Coming Together While Staying Apart

I have never participated in trench warfare and I am sure it was pretty grim for those who lived and suffered through it. I have spent plenty of time however ‘in the trenches’ in biotech. Just like the stories of war, I have made it through the tough times...

read more

Core (Values) Workout

Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done: run. Injury stopped me from running last fall and I’ve since seen orthopods and running experts galore. But it’s been...

read more

BioPharma M&A Drives More Efficient Resource Allocation

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. Read more. The post BioPharma M&A Drives More Efficient Resource Allocation appeared first on Atlas Venture.

read more

Call Me, Maybe

My first job at a public company was when I joined Biogen or Biogen Idec as it was then called. One of the rituals of the team was to listen in to the quarterly earnings calls, usually on speaker in a conference room as we drank our morning cup of joe and caught up...

read more

Wither New Biotech Startups?

Biotech is in the midst of an incredible era of innovation: new modalities and novel medicines delivering real value to patients, leading to a decade-long bull cycle. It’s been exhilarating to watch and participate in this market, and venture capital activity in...

read more